Abstract
A 75-year-old woman with rheumatoid arthritis (RA) who was receiving methotrexate (MTX) therapy developed Epstein-Barr virus (EBV)-associated CD8(+) T-cell lymphoproliferative disorder (LPD) and meningoencephalitis. She was successfully treated with acyclovir and corticosteroids plus MTX cessation. T-cell LPD is relatively rare in RA patients receiving MTX. To our knowledge, this is the first report of CD8(+) T-cell LPD with EBV genome occurring during MTX therapy for RA. EBV infection should be carefully monitored to assess severe EBV-associated complications.
MeSH terms
-
Acyclovir / therapeutic use
-
Aged
-
Antirheumatic Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Arthritis, Rheumatoid / immunology*
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology*
-
Epstein-Barr Virus Infections / complications
-
Epstein-Barr Virus Infections / drug therapy
-
Epstein-Barr Virus Infections / immunology*
-
Female
-
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics
-
Herpesvirus 4, Human / genetics
-
Herpesvirus 4, Human / isolation & purification
-
Humans
-
Immunocompromised Host
-
Immunophenotyping
-
Lymph Nodes / immunology
-
Lymph Nodes / pathology
-
Lymphoproliferative Disorders / drug therapy
-
Lymphoproliferative Disorders / immunology*
-
Lymphoproliferative Disorders / virology
-
Meningoencephalitis / drug therapy
-
Meningoencephalitis / immunology
-
Meningoencephalitis / virology
-
Methotrexate / adverse effects*
-
Methylprednisolone / therapeutic use
Substances
-
Antirheumatic Agents
-
Antiviral Agents
-
Acyclovir
-
Methylprednisolone
-
Methotrexate